{"entity":{"id":"nct06951503","kind":"trial","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 3 trial of Oxaliplatin and Bevacizumab in colorectal cancer, run by Akeso, now recruiting.","summary":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT06951503 by Akeso, with 560 participants planned, started 2025-05-27 and due to reach its primary completion in 2027-01-13. Interventions recorded: AK112, Oxaliplatin, Irinotecan, Leucovorin and 5-FU and Bevacizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06951503","url":"https://clinicaltrials.gov/study/NCT06951503"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":["antiangiogenic","monoclonal-antibody"],"targets":[],"drugs":["oxaliplatin","bevacizumab"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06951503","phase":"3","setting":"A Randomized, Controlled, Multicenter Phase III Clinical Study of AK112 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy in First-line Metastatic Colorectal Cancer","sponsor":"Akeso","participation":[{"nct":"NCT06951503","source":"https://clinicaltrials.gov/study/NCT06951503","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"6d5feab061f0fe1f40184859197d3b711e6fa4ca1be2494b1f3f81863e34c6a2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-04","leadSponsor":"Akeso","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":560,"enrolmentType":"ESTIMATED","siteCount":2,"recruitingSiteCount":2,"countries":["China"]}],"started":"2025-05-27","startedType":"actual","enrolled":560,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06951503/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}